Bunka Christopher's Form 4 filing
Lexaria Bioscience Corp. (LEXX) · filed Jul 30, 2025
- Accession no.
- 0001348362-25-000016
- Filed
- Jul 30, 2025
- Trade date
- Jul 29-30, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $25.2K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bunka ChristopherCIK 0001103780 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 29, 2025 | common shares | PPurchaseAcquired | +15,600 | $0.92 | +$14,352 | 270,012 | Indirect | |
| Jul 30, 2025 | common shares | PPurchaseAcquired | +11,900 | $0.91 | +$10,829 | 281,912 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.